RMR Wealth Builders’s Nektar Therapeutics NKTR Stock Holding History

RMR Wealth Builders’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-4	Closed	-$1K	–	500
2021 Q1	$1K	Hold	4	–	–	﹤0.01%	762
2020 Q4	$1K	Buy	+4	New	+$1.03K	﹤0.01%	506
2020 Q3	–	Sell	-4	Closed	-$2K	–	383
2020 Q2	$2K	Buy	+4	New	+$1.25K	﹤0.01%	415
2019 Q4	$1K	Buy	+4	New	+$1.16K	﹤0.01%	400

Other funds holding NKTR

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

RMR Wealth Builders's NKTR Position: Q2 2021 in Review

RMR Wealth Builders sold out of Nektar Therapeutics (NKTR) in Q2 2021, closing a stake of 4 shares — an estimated $1K sold.

RMR Wealth Builders first reported a position in NKTR in Q4 2019 and held it in 4 quarters. The position peaked at $2K in Q2 2020. 239 funds tracked by Wall St. Rank hold NKTR as of Q2 2021.

RMR Wealth Builders reported no remaining Nektar Therapeutics position as of Q2 2021 after selling out during the quarter.
RMR Wealth Builders sold 4 Nektar Therapeutics shares in Q2 2021, an estimated $1K.
RMR Wealth Builders first reported a position in Nektar Therapeutics in Q4 2019 and held it in 4 quarters.
RMR Wealth Builders's Nektar Therapeutics position peaked at $2K in Q2 2020.
239 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2021.

Based on RMR Wealth Builders's 13F filing for Q2 2021, filed 16 Aug 2021.